AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00695578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biafine
Description: Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
Study NCT00695578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysporin
Description: over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
Study NCT00006363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00006363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00006363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00006363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valspodar
Description: Given IV
Study NCT00006363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00006363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally
Study NCT00006363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous PBSCT
Study NCT00006363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous PBSCT
Study NCT00006363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00006363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Description: Undergo clinical observation
Study NCT00006363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02518620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
Study NCT00467909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micronutrients
Study NCT04389476 — intervention group
Intervention type: OTHER
Intervention: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)
Description: Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors.
Study NCT00006363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT00542568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPODURE (dermal Biopump for erythropoietin)
Description: Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
Study NCT01442038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Study NCT02275936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N91115
Description: S Nitrosoglutathione Reductase Inhibitor
Study NCT02743312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Weights
Description: Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
Study NCT02743312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Flex
Description: Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
Study NCT01442038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy.
Study NCT00089284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
Study NCT00089284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
Study NCT00089284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111Indium-Zevalin and 90Yttrium-Zevalin
Description: Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2\*, 4\*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
Study NCT02237911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic-based outpatient exercise group
Description: Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
Study NCT02237911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community-based exercise group
Description: Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
Study NCT04535765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early warm water sitz bath
Description: The experimental group started the warm water sitz bath 6 hours after the end of the hemorrhoid surgery.
Study NCT04535765 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regular time warm water sitz bath
Description: According to the routine, the control group started the warm water sitz bath on the first day after the hemorrhoid surgery.
Study NCT01730729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Description: Given orally
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulfate
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized isotonic saline
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Salbutamol
Description: Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Salbutamol
Description: Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
Study NCT02584699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
Study NCT04280146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: daily energy intake
Description: Investigate daily energy intake according to eating rate and food processing
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: Nebulized ipratropium bromide 250 mcg
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium bromide
Description: Nebulized ipratropium bromide 250 mcg
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone or Prednisolone
Description: Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
Study NCT02584738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone or Prednisolone
Description: Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
Study NCT02895984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session alcohol intervention (BMI)
Description: The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
Study NCT02157727 — intervention group
Intervention type: DEVICE
Intervention: Infants hospitalized in health facilities performing Tele-expertise
Study NCT02510742 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurostimulation
Description: Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
Study NCT02510742 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
Study NCT02783677 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous balloon angioplasty
Study NCT02147028 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal sparing whole brain radiotherapy
Description: 30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
Study NCT02147028 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional whole brain radiotherapy
Description: 30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
Study NCT02239224 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concentrate for solution for infusion
Study NCT00594997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
Study NCT00594997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (pre and post surveys)
Description: Students fill out a pre and post survey and then receive the same intervention given to the controls.
Study NCT02796482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: EnergieShake 1.5kcal Complete
Description: Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
Study NCT01118637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StopPulling.com
Description: subsidized access to an interactive self-help website for TTM
Study NCT01668199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Study NCT05067985 — intervention group
Intervention type: PROCEDURE
Intervention: covid 19 spinal anesthesia
Description: this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
Study NCT02633891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance exercise
Description: tailored balance exercise program
Study NCT02633891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: general health education and fall prevention classes
Study NCT02862704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG7-CART
Description: Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
Study NCT03558113 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: light induced fluorescence intraoral camera
Description: intraoral oral light induced fluorescence diagnostic camera
Study NCT03631147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 400mg bid for 8 weeks
Study NCT02239224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study NCT00478881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil HCl (Levitra, BAY38-9456)
Description: vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
Study NCT00478881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
Study NCT03031236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice
Description: The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
Study NCT01466179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle
Study NCT01640626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education package
Description: Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
Study NCT02921360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Study NCT02725853 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Application of 1.5 mA tDCS for 30 minutes
Study NCT02725853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Application of 1.5 mA tDCS for 30 minutes
Study NCT02725853 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Application of sham tDCS for 30 minutes
Study NCT02725853 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: personalized practice
Description: arm exercise consisting of whole arm movement within a restricted elbow range of motion
Study NCT02725853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized practice
Description: arm exercise consisting of whole arm movement within a restricted elbow range of motion
Study NCT02862262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARIES Bordetella Assay
Study NCT03829514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides >150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
Study NCT04174482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: morphological and functional evaluation of adult flat foot
Description: Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
Study NCT02685436 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole and domperidone
Description: wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
Study NCT03449147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet administered orally BID
Study NCT03449147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered orally BID
Study NCT03449147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 15 mg BID
Description: Gefapixant 15 mg tablet administered orally BID
Study NCT03449147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg BID
Description: Gefapixant 45 mg tablet administered orally BID
Study NCT02973022 — intervention group
Intervention type: OTHER
Intervention: CC&S
Description: Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC\&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
Study NCT02725853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-personalized practice
Description: arm exercise consisting of unrestricted whole arm movement
Study NCT02929173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allceram
Description: Pressed E-max coping veneered with E-max veneering system
Study NCT02929173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hybrid crown
Description: pressed Bio HPP coping veneered with visolign veneering system
Study NCT01885871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond QS Nd:YAG Laser
Description: Up to 2 laser treatments delivered 6 weeks apart
Study NCT01941043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-301
Study NCT01941043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01917032 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food
Description: 1 g orally on weekdays during 11 weeks
Study NCT01941043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04215588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostasis Management System Plus
Description: Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.
Study NCT04215588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activated Coagulation Timer System Plus
Description: The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.